These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 36247169)

  • 1. Effect of vasopressin V2-receptor antagonist tolvaptan on syndrome of inappropriate antidiuresis (SIAD) after transsphenoidal pituitary surgery: recovery of measured osmolality.
    Tosaka M; Yamaguchi R; Itabashi Y; Mukada N; Tsuneoka H; Takahashi K; Nakamura S; Nakazawa T; Yoshimoto Y
    Heliyon; 2022 Oct; 8(10):e10966. PubMed ID: 36247169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Case report: Twice-daily tolvaptan dosing regimen in a challenging case of hyponatremia due to SIAD.
    Arecco A; Demontis D; Della Sala L; Musso N; Gay S; Boschetti M; Ferone D; Gatto F
    Front Endocrinol (Lausanne); 2023; 14():1309657. PubMed ID: 38288467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tolvaptan in the Management of Acute Euvolemic Hyponatremia After Transsphenoidal Surgery: A Retrospective Single-Center Analysis.
    Indirli R; Ferreira de Carvalho J; Cremaschi A; Mantovani B; Sala E; Serban AL; Locatelli M; Bertani G; Carosi G; Fiore G; Tariciotti L; Arosio M; Mantovani G; Ferrante E
    Front Endocrinol (Lausanne); 2021; 12():689887. PubMed ID: 34108941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolvaptan for the treatment of the syndrome of inappropriate antidiuresis (SIAD).
    Tzoulis P; Kaltsas G; Baldeweg SE; Bouloux PM; Grossman AB
    Ther Adv Endocrinol Metab; 2023; 14():20420188231173327. PubMed ID: 37214762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.
    Schrier RW; Gross P; Gheorghiade M; Berl T; Verbalis JG; Czerwiec FS; Orlandi C;
    N Engl J Med; 2006 Nov; 355(20):2099-112. PubMed ID: 17105757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The V
    Marroncini G; Anceschi C; Naldi L; Fibbi B; Baldanzi F; Maggi M; Peri A
    J Endocrinol Invest; 2022 Sep; 45(9):1693-1708. PubMed ID: 35604542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Syndrome of inappropriate antidiuresis without involving inappropriate secretion of vasopressin in an elderly woman: effect of intravenous administration of the nonpeptide vasopressin V2 receptor antagonist OPC-31260.
    Kamoi K
    Nephron; 1997; 76(1):111-5. PubMed ID: 9171309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum and urine responses to the aquaretic agent tolvaptan in hospitalized hyponatremic patients.
    Vaghasiya RP; DeVita MV; Michelis MF
    Int Urol Nephrol; 2012 Jun; 44(3):865-71. PubMed ID: 21607553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of Hyponatremia with Tolvaptan in a Patient after Neurosurgical Treatment of a Pituitary Tumor: Case Report and Review of Literature.
    Ichimura S; Fahlbusch R; Lüdemann W
    J Neurol Surg Rep; 2015 Nov; 76(2):e279-81. PubMed ID: 26623242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Difference in solute excretion during correction of hyponatremic patients with cirrhosis or syndrome of inappropriate secretion of antidiuretic hormone by oral vasopressin V2 receptor antagonist VPA-985.
    Decaux G
    J Lab Clin Med; 2001 Jul; 138(1):18-21. PubMed ID: 11433224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis.
    Cárdenas A; Ginès P; Marotta P; Czerwiec F; Oyuang J; Guevara M; Afdhal NH
    J Hepatol; 2012 Mar; 56(3):571-8. PubMed ID: 22027579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic effects of tolvaptan, a potent, selective nonpeptide vasopressin V2 receptor antagonist, in rats with acute and chronic severe hyponatremia.
    Miyazaki T; Yamamura Y; Onogawa T; Nakamura S; Kinoshita S; Nakayama S; Fujiki H; Mori T
    Endocrinology; 2005 Jul; 146(7):3037-43. PubMed ID: 15831573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Experience of the Efficacy and Safety of Low-dose Tolvaptan Therapy in a UK Tertiary Oncology Setting.
    Chatzimavridou-Grigoriadou V; Al-Othman S; Brabant G; Kyriacou A; King J; Blackhall F; Trainer PJ; Higham CE
    J Clin Endocrinol Metab; 2021 Oct; 106(11):e4766-e4775. PubMed ID: 33693944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new method of intermittent lower dose of tolvaptan combined with fluid restriction to treat the syndrome of inappropriate antidiuresis: A case report.
    Yuan X; Pan H; Zhu H; Li J; Miao H; Ke X; Chen S
    Medicine (Baltimore); 2019 Oct; 98(43):e17586. PubMed ID: 31651865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of oral tolvaptan for severe edema and hyponatremia in a patient with refractory nephrotic syndrome.
    Saimiya M; Kaku Y; Nishimura M
    CEN Case Rep; 2021 Nov; 10(4):523-526. PubMed ID: 33904139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapidity of Correction of Hyponatremia Due to Syndrome of Inappropriate Secretion of Antidiuretic Hormone Following Tolvaptan.
    Morris JH; Bohm NM; Nemecek BD; Crawford R; Kelley D; Bhasin B; Nietert PJ; Velez JCQ
    Am J Kidney Dis; 2018 Jun; 71(6):772-782. PubMed ID: 29478867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolvaptan Versus Fluid Restriction in the Treatment of Hyponatremia Resulting from SIADH Following Pituitary Surgery.
    Kleindienst A; Georgiev S; Schlaffer SM; Buchfelder M
    J Endocr Soc; 2020 Jul; 4(7):bvaa068. PubMed ID: 32666012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of Serum Sodium Levels during Chemotherapy Using Selective Arginine Vasopressin V2-Receptor Antagonist Tolvaptan in a Four-Year-Old Girl with a Suprasellar Germ Cell Tumor.
    Hiroshima S; Nyuzuki H; Sasaki S; Ogawa Y; Nagasaki K
    Children (Basel); 2021 Apr; 8(4):. PubMed ID: 33920088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolvaptan use in cancer patients with hyponatremia due to the syndrome of inappropriate antidiuretic hormone: a post hoc analysis of the SALT-1 and SALT-2 trials.
    Gralla RJ; Ahmad F; Blais JD; Chiodo J; Zhou W; Glaser LA; Czerwiec FS
    Cancer Med; 2017 Apr; 6(4):723-729. PubMed ID: 28251822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure.
    Katsumata M; Hirawa N; Sumida K; Kagimoto M; Ehara Y; Okuyama Y; Fujita M; Fujiwara A; Kobayashi M; Kobayashi Y; Yamamoto Y; Saka S; Yatsu K; Fujikawa T; Toya Y; Yasuda G; Tamura K; Umemura S
    Clin Exp Nephrol; 2017 Oct; 21(5):858-865. PubMed ID: 28190113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.